Trevena Receives Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
Trevena Receives Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
Trevena 收到來自中國合作伙伴的里程碑式付款江蘇恩華製藥
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received a $3 million milestone payment from its partner in China for the Chinese approval of OLINVYK. Jiangsu Nhwa Pharmaceutical Co. Ltd. (Nhwa) holds an exclusive license agreement to develop, manufacture, and commercialize OLINVYK in China.
Trevena, Inc.（納斯達克股票代碼：TRVN）， 一家專注於中樞神經系統（CNS）疾病患者新藥開發和商業化的生物製藥公司今天宣佈，它已從中國合作伙伴那裏獲得300萬美元的里程碑式付款，用於中國批准OLINVYK。江蘇恩華藥業有限公司Ltd.（Nhwa）持有在中國開發、製造和商業化OLINVYK的獨家許可協議。